Methods of treating TNF alpha -mediated disease using chimeric anti-TNF antibodies - Patent US5919452(A)

Filed: Feb 04, 1994

Published: Jul 06, 1999

Abstract

Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which compounds are specific for tumor necrosis factor- alpha (TNF alpha ) or tumor necrosis factor- beta (TNF beta ) and which are useful for in vivo therapy or diagnosis of TNF alpha -mediated pathologies and conditions, wherein the anti-TNF compound is selected from the group consisting of at least one of an immunoglobulin variable region, a fragment of a TNF receptor and an anti-TNF peptide, such as a structural analog of a anti-TNF antibody fragment or a TNF receptor fragment.

Applicants

UNIV NEW YORK
CENTOCOR INC

Inventors

DADONNA PETER
LE JUNMING
GHRAYEB JOHN
SEIGAL SCOTT
VILCEK JAN
KNIGHT DAVID

Application Number

192861

Priority Claims

US67082791

Family Members

US5656272(A) - Methods of treating TNF- alpha -mediated Crohn's disease using chimeric anti-TNF antibodies

US5919452(A) - Methods of treating TNF alpha -mediated disease using chimeric anti-TNF antibodies

US6284471(B1) - Anti-TNFa antibodies and assays employing anti-TNFa antibodies

Classification Codes

C07K14/525, C07K16/24, A61K38/00, C07K14/435, C07K16/18